Success Metrics

Clinical Success Rate
89.7%

Based on 26 completed trials

Completion Rate
90%(26/29)
Active Trials
3(7%)
Results Posted
46%(12 trials)
Terminated
3(7%)

Phase Distribution

Ph phase_2
14
34%
Ph early_phase_1
1
2%
Ph phase_1
9
22%
Ph phase_3
12
29%
Ph not_applicable
4
10%
Ph phase_4
1
2%

Phase Distribution

10

Early Stage

14

Mid Stage

13

Late Stage

Phase Distribution41 total trials
Early Phase 1First-in-human
1(2.4%)
Phase 1Safety & dosage
9(22.0%)
Phase 2Efficacy & side effects
14(34.1%)
Phase 3Large-scale testing
12(29.3%)
Phase 4Post-market surveillance
1(2.4%)
N/ANon-phased studies
4(9.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.7%

26 of 30 finished

Non-Completion Rate

13.3%

4 ended early

Currently Active

3

trials recruiting

Total Trials

41

all time

Status Distribution
Active(3)
Completed(26)
Terminated(4)
Other(8)

Detailed Status

Completed26
unknown8
Terminated3
Active, not recruiting2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
41
Active
3
Success Rate
89.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.4%)
Phase 19 (22.0%)
Phase 214 (34.1%)
Phase 312 (29.3%)
Phase 41 (2.4%)
N/A4 (9.8%)

Trials by Status

completed2663%
withdrawn12%
active_not_recruiting25%
recruiting12%
unknown820%
terminated37%

Recent Activity

Clinical Trials (41)

Showing 20 of 41 trialsScroll for more
NCT01409161Phase 2

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Recruiting
NCT02339740Phase 3

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Active Not Recruiting
NCT04919369Phase 1

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Active Not Recruiting
NCT02688140Phase 3

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Completed
NCT00382200Phase 1

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Completed
NCT03878524Phase 1

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated
NCT06181838Not Applicable

Comparison of Quality of Life in Moderate Acne Vulgaris Patients Based on Acne-QoL-INA Using Standard Therapy With and Without Acne Lesions Extraction

Unknown
NCT02842827Phase 1

A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

Completed
NCT00003601Phase 2

Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome

Completed
NCT03999684Phase 2

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

Completed
NCT00492856Phase 3

S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

Completed
NCT00551460Phase 2

S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Completed
NCT04080869Phase 2

Retinyl Palmitate-loaded Ethosomes in Acne Vulgaris

Completed
NCT00866918Phase 3

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Completed
NCT02620813Early Phase 1

De Novo Lipogenesis of Sebaceous Glands in Acne

Completed
NCT02273102Phase 1

Study of TCP-ATRA for Adult Patients With AML and MDS

Completed
NCT02249767Phase 3

Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel

Completed
NCT01243450Phase 3

Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo

Completed
NCT00006239Phase 1

Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer

Completed
NCT01820624Phase 1

Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed

Drug Details

Intervention Type
DRUG
Total Trials
41